Skip to content
Thursday 3 September 2026London --:--Frankfurt --:--Zurich --:--
NewslettersSearchEN · DE · FR
MorningWire

European business, markets and politics

FTSE 100
10,755.32
-0.01%
DAX
25,867.11
+0.11%
CAC 40
8,266.34
-0.17%
STOXX 50
6,360.79
-0.02%
  • Europe
  • Markets
  • Business
  • Economy
  • Regulation
  • Politics
  • Opinion
More
GermanyFranceEU InstitutionsCompetitionPublic AffairsBankingTechnologyEnergy
  • Germany
  • France
  • Europe
  • Markets
  • Business
  • Economy
  • Regulation
  • Politics
  • Opinion
  • DE
Wednesday 06 July 2016 2:22 pm

Sanofi and US army combine efforts in search for Zika vaccine

By: Oliver Gill

Add as a preferred source on Google

French pharmaceuticals firm Sanofi today revealed it has teamed up with the US military to accelerate development of a vaccine for the Zika virus which has swept through South and Central America.

Sanofi said that it had agreed to work with the Walter Reed Army Institute of Research (WRAIR) which will hand over its Zika vaccine technology. The French firm would further develop the research while giving the WRAIR access to its findings.

"We're looking at… collaborating to get into the clinic quicker to provide a vaccine in response to the current emergency,” said John Shiver of Sanofi.

Global health officials are still trying to fully understand the Zika virus. After a high profile outbreak in Brazil last year, local government called a state of emergency November 2015.

In February 2016, the World Health Organisation announced a global public health emergency across 20 countries in the Americas due to the rapid spread of the virus.

The outbreak in Brazil has threaten to overshadow the upcoming Olympic Games that start on 5 August 2016. A number of athletes, such as golfers Rory McIlroy and Jason Day, have withdrawn from competing on health concerns.

WRAIR had managed to create an experimental vaccine that gave 100 percent protection in mice against the Zika virus, according to a study published last week.

Meanwhile, Sanofi was expecting to commence its own trials in 2017 after leveraging its knowledge of mosquito-borne diseases such as dengue fever.

Share this article

  • Facebook
  • X
  • LinkedIn
  • WhatsApp
  • Email

Similarly tagged content:

Sections

  • Life&Style
  • News

Categories

  • Sport
  • Tech

Trending Articles

  • Vodafone and Deliveroo look to patch up Reform ties after Yusuf prison threats

  • Trio of firms poised to quit London Stock Exchange as exodus gathers pace

  • Easyjet’s over-60s recruitment push is economically necessary

  • Jim O’Neill: Capital gains tax hike ‘looms’ as top option for Burnham

  • ‘Large tax hikes on the way’: How the global bond rout is boxing in Healey

More from Morning Wire

  • ILiAD Biotechnologies Expands Board of Directors and Appoints Chief Business Officer

    Business Wire
  • Dolly Parton: The rhinestone capitalist

    Opinion
    Dollywood gift shop with Dolly Parton t-shirt, books, mugs, and colorful floral display. A person browses merchandise.
  • Mbappe-backed brand set for London store in Harrods

    Sport Business
    Kylian Mbappé in a cream-colored Adidas track jacket with the Real Madrid crest, looking up with a thoughtful expression
  • Lone Star Funds Completes Sale of Vigor Marine Group

    Business Wire
  • Trading Central Launches a UCITS ETF

    Business Wire
  • Stealth taxes intensify London first time buyer struggle

    Property
    Row of classic London terraced houses with white facades and green doors, indicating UK property.
  • Why Manchester City’s £86m Bouaddi signing should ring alarm bells in French football

    Sport Business
    A male soccer player with long dark curly hair in a white LOSC Lille jersey adjusts his hair on the field.
  • Bayern Munich old boys in takeover of Portuguese top-flight club

    Sport Business
    Thomas Müller in a white MLS jersey looking forward with fans in the background at a stadium event.
MorningWire

Independent European business, markets and political news for decision-makers.

Morning Briefing

Europe

  • Germany
  • France
  • EU Institutions
  • Europe

Business

  • Markets
  • Business
  • Economy
  • Regulation
  • Competition
  • Public Affairs

Editorial

  • Opinion
  • Editorial Policy
  • Corrections
  • Contact

Company

  • About Morning Wire
  • Privacy Policy
  • Terms of Use
  • Cookie Policy
© 2026 Morning Wire Ltd · Published by Morning Wire Media, Bahnhofstrasse 65, 8001 Zürich, Switzerland
Privacy · Terms · Cookies · Facebook